Dilato and BP will be there until the company is bought by a major.
The only way I can see Dilato reducing is to help get a strategic partner set.
It's a publicly company's responsibility to extract the highest value for its assets/stock.
I believe an OTC listing would help PO3 truly reflect the value of its technology in its market cap.
PO3 Price at posting:
$4.52 Sentiment: Buy Disclosure: Held